<DOC>
	<DOCNO>NCT01521715</DOCNO>
	<brief_summary>Patients advance renal cell carcinoma ( RCC ) classify accord Memorial Sloan-Kettering Cancer Center ( MSKCC ) criteria three risk-groups : favourable , intermediate poor . To knowledge one study examine poor risk group ( Hudes et al . ) , lead approval temsirolimus population . However temsirolimus demonstrate low response rate 8.6 % accord Response Evaluation Criteria In Solid Tumor ( RECIST ) criterion Progression free Survival ( PFS ) 5.5 month patient suitable temsirolimus treatment . Thus , clinical routine high-risk patient also treat multi Tyrosinkinase Inhibitors ( mTKI ) . To date , prospective data acquisition control effectiveness mTKI-treatment high-risk patient conduct . Pazopanib recently approve first-line treatment advance renal cell carcinoma Europe USA . In pivotal Phase III trial nine patient pazopanib group poor risk accord MSKCC risk criterion analysis subgroup perform . Therefore data group patient high medical need need . Currently well-established predictive prognostic biomarkers RCC-mTKI treatment . This one important scientific question field . In addition clinical endpoint study , comprehensive biomarker program seek evaluate biomarker candidate help learn effect pazopanib human organism .</brief_summary>
	<brief_title>First Line Pazopanib Poor Risk Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Histologically confirm metastatic locally advanced ( define non operable tumor ) , predominantly clear cell renal cell carcinoma . At least three follow five predictor short survival require : Lactate Dehydrogenase ( LDH ) &gt; 1.5 x Upper Limit Normal ( ULN ) Hemoglobin &lt; Lower Limit Normal ( LLN ) correct serum calcium level &gt; 10 mg/dl ( 2.5 mmol/l ) time initial diagnosis renalcell carcinoma occurrence metastases less 1 year Karnofsky Status 60 70 Karnofsky Status ≥ 60 Age ≥ 18 year legal age consent great 18 year Dated sign write informed consent prior performance studyspecific procedure assessments Patients least one measurable disease , define RECIST 1.1 Fresh archive tumor tissue provide subject biomarker analysis treatment pazopanib . Adequate organ system function define : Subjects may transfusion within 7 day screen assessment . Subjects receive anticoagulant therapy eligible International Normalized Ratio ( INR ) stable within recommended range desire level anticoagulation . Concomitant elevation bilirubin aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 1.0 x ULN permit . Patients Gilbert 's disease elevation indirect bilirubin consider like patient normal bilirubin . Compliance patient Other malignancy . ( Patients undergone prior radical partial nephrectomy RCC allow ) . Subjects another malignancy diseasefree five year , subject history completely resect nonmelanomatous skin carcinoma successfully treat situ carcinoma eligible . Prior systemic treatment renal cell carcinoma . ( NB : treatment , neoadjuvant , adjuvant locally advanced metastatic RCC permit . ) History clinical evidence central nervous system ( CNS ) metastases leptomeningeal carcinomatosis , except individual previouslytreated CNS metastasis , asymptomatic , requirement steroid antiseizure medication 6 month prior first dose study drug . Screening CNS image study ( compute tomography ( CT ) magnetic resonance imaging ( MRI ) require clinically indicated subject history CNS metastases . Clinically significant gastrointestinal abnormality may increase risk gastrointestinal bleeding Clinically significant gastrointestinal abnormality may affect absorption investigational product include , limited : Malabsorption syndrome , major resection stomach small bowel . Presence uncontrolled infection ( &gt; grade 2 NCICTCAE Version 4.03 ) . Corrected QT interval ( QTc ) &gt; 480 msec use Bazett 's formula History one follow cardiovascular condition within past 6 month : Myocardial infarction Cardiac angioplasty stenting Unstable angina Coronary artery bypass graft surgery Symptomatic peripheral vascular disease Class III IV congestive heart failure , define New York Heart Association ( NYHA ) Poorly control hypertension History cerebrovascular accident include transient ischemic attack ( TIA ) , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month . Note : Subjects recent DVT treat therapeutic anticoagulating agent least 6 week eligible Prior major surgery trauma within 28 day prior first dose study drug and/or presence nonhealing wound , fracture , ulcer . Evidence active bleeding bleed diathesis . Known endobronchial lesion lesion infiltrate major pulmonary vessel Hemoptysis excess 2.5 ml ( one half teaspoon ) within 8 week prior first dose study drug Any serious unstable preexist medical , mental , condition , medical , social mental impairment drug abuse could comprise interfere subject 's safety , provision inform consent , compliance study procedure . Unable unwilling discontinue use prohibit medication least 14 day five halflives drug ( whichever longer ) prior first dose study drug duration study . Simultaneous participation another clinical drug study Known infection Human Immunodeficiency Virus ( HIV ) chronic hepatitis B C Pregnant breastfeed woman . Female subject childbearing potential need negatively test prior close start therapy possible , least within 14 day . Women participate trial require use adequate contraception . Female subject lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug Subjects unable take oral medication Known hypersensitive reaction component study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>